Nuvation Bio price target lowered to $6 from $10 at RBC Capital

June 18, 2025 01:02 AM AEST | By EODHD

Google News:

Nuvation Bio price target lowered to $6 from $10 at RBC Capital — Image source: Kalkine Media

Recent News

Gold Resource Corporation Adds to Board of Directors

Platinum Asset Management Adjusts Course Amid Outflows and Merger Talk...

Equity Trustees (ASX:EQT) Pays Fine Over Fund Disclosure Issues

Raiden Resources (ASX:RDN, DAX:YM4) Identifies Potential Epithermal Fe...

RBC Capital lowered its price target on Nuvation Bio stock (NYSE:NUVB) to $6.00 from $10.00 on Tuesday, while maintaining an Outperform rating following the company’s recent transformation into a commercial-stage biotech. The stock, currently trading at $1.78, has declined over 26% in the past week, according to InvestingPro data. The firm’s adjustment comes after Nuvation Bio received approval for its drug Ibtrozi, marking a significant milestone for the company as it enters the commercial market. RBC Capital identified potential challenges for Ibtrozi’s launch, including patient identification issues and near-term competitive pressures in the marketplace. Despite these concerns, the firm believes Ibtrozi’s favorable profile, long treatment duration, and improving diagnosis rates outweigh the challenges and could drive success over the mid to longer term.

The research firm projects Ibtrozi could achieve $430 million in peak worldwide revenues, noting that the current valuation "steeply discounts" Nuvation Bio’s newly realized commercial opportunity. In other recent news, Nuvation Bio has received full approval from the U.S. Food and Drug Administration for its lung cancer drug, IBTROZI, designed to treat advanced ROS1-positive non-small cell lung cancer. The approval is based on favorable results from the TRUST-I and TRUST-II studies, which reported high response rates in both treatment-naïve and previously treated patients. Following this approval, IBTROZI is now available for order in the United States at a monthly price of $29,488.

Analysts from H.C. Wainwright and JMP Securities have maintained their optimistic ratings on Nuvation Bio, with price targets of $10 and $6, respectively, reflecting confidence in IBTROZI’s competitive profile in the market. Citizens JMP also reiterated its Market Outperform rating and $6 price target, noting the company’s detailed launch plans for the drug. Nuvation Bio has also launched NuvationConnect, a program offering financial assistance and support for eligible patients prescribed IBTROZI. The company plans to host a conference call to discuss the approval and commercialization plans further.

These developments mark Nuvation Bio’s transition from a development-stage to a commercial-stage company. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.